...
首页> 外文期刊>The American heart journal >EPICOR (long-tErm follow-up of antithrombotic management Patterns in acute CORonary syndrome patients) study: Rationale, design, and baseline characteristics
【24h】

EPICOR (long-tErm follow-up of antithrombotic management Patterns in acute CORonary syndrome patients) study: Rationale, design, and baseline characteristics

机译:EPICOR(急性冠状动脉综合征患者的长期血栓抗栓治疗模式随访)研究:基本原理,设计和基线特征

获取原文
获取原文并翻译 | 示例
           

摘要

Background: There is limited information about patterns of use of newer antithrombotic drugs in patients with acute coronary syndromes (ACS) in a real-life setting. The effectiveness, safety and cost-effectiveness of potential combinations during hospitalization, the duration of therapies, interruptions, or discontinuations as well as their reasons and possible consequences are unknown. Methods: EPICOR (NCT01171404) is a prospective, multinational, observational study on patients discharged after a hospitalization for an ACS with 2-year follow-up. The study is designed to describe the patterns of antithrombotic use and to evaluate potential differences in short- and long-term clinical outcomes (ischemic and bleeding events), quality of life and economic impact associated with initial combinations during hospitalization, and treatment duration, discontinuations, or interruptions and their reasons after discharge in different clinical environments. Results: Between September 1, 2010, and March 31, 2011, 10,568 consecutive patients surviving an ACS (4943 with ST-segment elevation myocardial infarction, and 5625 with non-ST-segment elevation ACS) were enrolled from 555 hospitals in 20 countries from 4 pre-defined regions: Northern Europe (n = 3,782), Southern Europe (n = 2,337), Eastern Europe (n = 2,380), and Latin America (n = 2,069). Pre- and in-hospital management and outcomes were recorded, with a special focus on antithrombotic therapies and ischemic and bleeding events. Changes in antithrombotic treatments and outcomes are currently being registered during the planned 24-month follow-up. Conclusion: EPICOR will show current patterns of antithrombotic use during hospitalization and after discharge in 'real-world' patients with ACS, allowing exploration of potential differences in clinical outcomes, quality of life, and costs related to the different antithrombotic practice patterns. ? 2013 Mosby, Inc.
机译:背景:在现实生活中,有关急性冠状动脉综合征(ACS)患者使用新型抗血栓药物的模式的信息有限。尚不清楚住院期间潜在组合的有效性,安全性和成本效益,治疗的持续时间,中断或中止的时间以及其原因和可能的后果。方法:EPICOR(NCT01171404)是一项前瞻性,多国,观察性研究,研究对象为ACS住院2年后随访的出院患者。该研究旨在描述抗栓剂的使用方式,并评估短期和长期临床结局(缺血和出血事件)的潜在差异,与住院期间初始组合相关的生活质量和经济影响以及治疗持续时间,停药,或在不同临床环境中出院后出现中断及其原因。结果:从2010年9月1日至2011年3月31日,从20个国家/地区的555家医院招募了10568例幸存的ACS患者(4943例ST段抬高型心肌梗死和5625例非ST段抬高型ACS)。 4个预定义区域:北欧(n = 3,782),南欧(n = 2,337),东欧(n = 2,380)和拉丁美洲(n = 2,069)。记录了院前和院内的管理和结果,特别关注抗血栓治疗以及缺血和出血事件。目前正在计划的24个月随访期间记录抗血栓治疗方法和结局的变化。结论:EPICOR将显示“现实” ACS患者在住院期间和出院后的抗血栓使用现状,从而探索与不同抗血栓治疗方式相关的临床结局,生活质量和费用方面的潜在差异。 ? 2013 Mosby,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号